Advanced Search

 

Study ID Status Title Patient Level Data
102396/002 Completed Study in order to evaluate reactogenicity and immunogenicity of GlaxoSmithKline Biologicals' experimental influenza vaccine in an elderly population aged over 65 years (>= 65 years-old) and previously vaccinated in 2003 with the experimental influenza vaccine in the Explo-Flu-001 clinical trial
102500-060 Completed Double-blind randomised, multicentre, comparative phase III vaccination study to determine the immunogenicity and reactogenicity of an investigational influenza vaccine formulation versus the standard formulation of Influsplit SSW® 2004/2005 in subjects at least 18 years old.
102547 Completed Evaluate immunogenicity,safety & reactogenicity of a booster dose of Hib-MenC conjugate vaccine when given to healthy subjects aged 13-14 months who were primed with 3 doses of Hib-MenC vs a booster dose of Infanrix hexa given to subjects primed with 3 doses of Infanrix hexa and Meningitec Study Listed on ClinicalStudyDataRequest.com
102587 Completed A Single-Dose, Open-Label, Randomized, Three-Way Cross-Over Study in Healthy Subjects to Evaluate the Relative Bioequivalence of Two New Small Tablet Formulations of Lapatinib (GW572016)
102761 Completed An Open-Label Randomized Study with 3 Cohorts of 3-Way Crossovers to Investigate the Safety Tolerability and Pharmacokinetics of 45mg Oral Doses of GW823093C and 500mg BID Oral Doses of Metformin (Cohort 1) 8mg Oral Doses of Rosiglitazone (Cohort 2) and 45mg Oral Doses of Pioglitazone (Cohort 3) Study Listed on ClinicalStudyDataRequest.com
102860 Completed A Two-Part, Randomized, Placebo-Controlled Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Single, Oral Doses of the Thrombopoietin Receptor Agonist, Eltrombopag; and the Effect of Eltrombopag on Cardiac Repolarization as Compared to Placebo and Single Oral Doses of Moxifloxacin in Healthy Adult Subjects
102861 Completed An Open-Label Mass Balance Study to Investigate the Metabolic Disposition of a Single Oral Dose of 14C SB-497115-GR in Healthy Male Subjects.
102863 Completed A randomized, open-label, two-period, period-balanced, crossover study with three parallel groups to evaluate the relative bioavailability of single oral doses of SB-497115-GR (eltrombopag) phase III tablets [50 mg, 75 mg, 100 mg] compared to SB-497115-GR phase II tablets [25mg and 50 mg] in healthy
102871 Completed HZC102871: A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
102881 Terminated A PhaseIIb, 96 week, randomised, partially double-blinded, multicentre, parallel group, repeat dose study to evaluate the safety, tolerability, PK and antiviral effect of GW873140 in combination with COMBIVIR (lamivudine and zidovudine) upon selected immunological and virological markers of HIV-1 infection in antiretroviral therapy naive adults
102932 Completed An open-label, randomised, 3-way crossover single dose study to demonstrate dose proportionality of fluticasone furoate (FF) and equivalence of vilanterol (VI) when administered as FF/VI inhalation powder from the novel dry powder inhaler in healthy subjects. Study Listed on ClinicalStudyDataRequest.com
102934 Completed An open-label, non-randomised, three-way crossover, single dose study to determine the absolute bioavailability of fluticasone furoate (FF)/GW642444 Inhalation Powder, in healthy subjects Study Listed on ClinicalStudyDataRequest.com
102936 Completed A randomised, placebo-controlled, four-way crossover repeat dose study to evaluate the effect of the inhaled fluticasone furoate (FF)/GW642444M combination on electrocardiographic parameters, with moxifloxacin as a positive control, in healthy subjects Study Listed on ClinicalStudyDataRequest.com
102942 Completed A randomized, double-blind, placebo-controlled, two-way crossover 14-day study to investigate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat dose inhaled fluticasone furoate 100ug (micrograms) in children aged 5-11 years with persistent asthma Study Listed on ClinicalStudyDataRequest.com
102970 Completed HZC102970: A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
103078 Completed An open, randomised, crossover study to assess the pharmacokinetics and tolerability of single doses of LAPDAP™, artesunate, and LAPDAP plus artesunate Study Listed on ClinicalStudyDataRequest.com
103094 Completed ARI103094-Follow-Up Study for REDUCE Study Subjects Study Listed on ClinicalStudyDataRequest.com
103096 Completed A randomised, double blind, placebo controlled, incomplete block, five-way cross-over study to investigate the effect of one week repeat dosing of GW685698X and inhaled fluticasone propionate (FP) on twenty-four hour serum cortisol in healthy subjects. Study Listed on ClinicalStudyDataRequest.com
103104 Completed A randomized, crossover, 3-period, 2-way interaction study to evaluate potential drug interactions between WELLBUTRIN XL® and citalopram in healthy volunteers
103106 Completed An open-label, 2-period, sequential treatment, 1-way drug interaction study to evaluate the effect of ritonavir on bupropion pharmacokinetics in healthy volunteers Study Listed on ClinicalStudyDataRequest.com
103205 Completed A Bioequivalence Study With a Combination Tablet Formulation of Rosiglitazone and Metformin (2 mg/500 mg) Compared to Concomitant Dosing of Rosiglitazone 2 mg and Metformin 500 mg Commercial Tablets in Chinese Healthy Male Subjects.
103268 Completed An open label, randomised, single dose, three-way crossover study to investigate the relative bioavailability of two different formulations of GSK163090 and the effect of food on the pharmacokinetics of a tablet formulation in healthy male and female volunteers
103304-001 Completed Study in an elderly population aged over 65 years (>= 65 years-old) in order to evaluate reactogenicity and immunogenicity of GlaxoSmithKline Biologicals' experimental Influenza vaccines, administered intramuscularly as compared to Fluarix vaccine
103366 Completed Open, multicentric, post-marketing surveillance study to evaluate safety and reactogenicity of GSK Bio's live attenuated oral Human Rotavirus (HRV) vaccine, Rotarix when administered according to Prescribing Information, in Filipino subjects aged at least 6 weeks of age at the time of first vaccination
103367 Completed A single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.